Synthesis of a nucleoside phosphoramidate prodrug inhibitor of HCV NS5B polymerase: Phenylboronate as a transient protecting group

Organic Process Research and Development

Volumn 18, Issue 6, 2014, Pages 717-724

  Mayes, Benjamin A ^a   Arumugasamy, Jeevanandam ^a   Baloglu, Erkan ^a   Bauer, David ^a   Becker, Alan ^a   Chaudhuri, Narayan ^a   Latham, G Mark ^a   Li, Jie ^a   Mathieu, Steve ^a   McGarry, F Patrick ^a   Rosinovsky, Elodie ^a   Stewart, Alistair ^a   Trochet, Christophe ^a   Wang, Jingyang ^a   Moussa, Adel ^a  

^a Idenix Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMISTRY;

HEPATITIS C VIRUS NS5B POLYMERASE; PHENYLBORONIC ACIDS; PHOSPHORAMIDATES; PRODRUG INHIBITORS; PROTECTING GROUP; SYNTHESIS AND CHARACTERIZATIONS; SYNTHETIC METHODOLOGY; SYNTHETIC PROCESS;

VIRUSES;

EID: 84903196287     PISSN: 10836160     EISSN: 1520586X     Source Type: Journal    
DOI: 10.1021/op500042u     Document Type: Article

References (35)

1. Lee, L. Y.; Tong, C. Y. W.; Wong, T.; Wilkinson, M. Int. J. Clin. Pract. 2012, 66, 342-355
2. Shepard, C. W.; Finelli, L.; Alter, M. J. Lancet Infect. Dis. 2005, 5, 558-567
3. American Association for the Study of Liver Diseases Hepatitis C Guidelines 2012. Gaetano, J. N.; Desai, A. P.; Reau, N. Clin. Med. Insights: Ther. 2012, 4, 39-56
4. Thompson, A.; Patel, K.; Tillman, H.; McHutchison, J. G. J. Hepatol. 2009, 50, 184-194
5. Gardelli, C.; Attenni, B.; Donghi, M.; Meppen, M.; Pacini, B.; Harper, S.; Di Marco, A.; Fiore, F.; Giuliano, C.; Pucci, V.; Laufer, R.; Gennari, N.; Marcucci, I.; Leone, J. F.; Olsen, D. B.; MacCoss, M.; Rowley, M.; Narjes, F. J. Med. Chem. 2009, 52, 5394-5407
6. The recent regulatory approval of sofosbuvir has clinically validated this target: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM371877.pdf (Accessed 25 November 2013).
7. Pierra, C.; Amador, A.; Benzaria, S.; Cretton-Scott, E.; D'Amours, M.; Mao, J.; Mathieu, S.; Moussa, A.; Bridges, E. G.; Standring, D. N.; Sommadossi, J.-P.; Storer, R.; Gosselin, G. J. Med. Chem. 2006, 49, 6614-6620
8. Donghi, M.; Attenni, B.; Gardelli, C.; Di Marco, A.; Fiore, F.; Giuliano, C.; Laufer, R.; Leone, J. F.; Pucci, V.; Rowley, M.; Narjes, F. Bioorg. Med. Chem. Lett. 2009, 19, 1392-1395
9. Meppen, M.; Pacini, B.; Bazzo, R.; Koch, U.; Leone, J. F.; Koeplinger, K. A.; Rowley, M.; Altamura, S.; Di Marco, A.; Fiore, F.; Giuliano, C.; Gonzalez-Paz, O.; Laufer, R.; Pucci, V.; Narjes, F.; Gardelli, C. Eur. J. Med. Chem. 2009, 44, 3765-3770
10. Sommadossi, J.-P.; Gosselin, G.; Pierra, C.; Perigaud, C.; Peyrottes, S. Patent Appl. WO2008082601, 2008.
11. Sommadossi, J.-P.; Gosselin, G.; Pierra, C.; Perigaud, C.; Peyrottes, S. Patent Appl. US20090169504, 2009.
12. Atherton, F. R.; Openshaw, H. T.; Todd, A. R. J. Chem. Soc. 1945, 660-663
13. Georgiev, E. M.; Kaneti, J.; Troev, K.; Roundhill, D. M. J. Am. Chem. Soc. 1993, 115, 10964-10973
14. Attenni, B.; Donghi, M.; Gardelli, C.; Meppen, M.; Narjes, F.; Pacini, B. Patent Appl. WO2008142055, 2008.
15. Hayakawa, Y.; Aso, Y.; Uchiyama, M.; Noyori, R. Tetrahedron Lett. 1983, 24, 1165-1168
16. Uchiyama, M.; Aso, Y.; Noyori, R.; Hayakawa, Y. J. Org. Chem. 1993, 58, 373-379
17. MacCoss, M.; Olsen, D. B.; Donghi, M.; Gardelli, C.; Harper, S.; Meppen, M.; Narjes, F.; Pacini, B. WO2007095269, 2007.
18. Narjes, F.; Gardelli, C.; Donghi, M.; Attenni, B.; Durette, P. L. WO2008085508, 2008.
19. McGuigan, C.; Madela, K.; Aljarah, M.; Gilles, A.; Brancale, A.; Zonta, N.; Chamberlain, S.; Vernachio, J.; Hutchins, J.; Hall, A.; Ames, B.; Gorovits, B.; Ganguly, B.; Kolykhalov, A.; Wang, J.; Muhammad, J.; Patti, J. M.; Henson, G. Bioorg. Med. Chem. Lett. 2010, 20, 4850-4854
20. McGuigan, C.; Madela, K.; Aljarah, M.; Gilles, A.; Battina, S. K.; Ramamurty, C. V. S.; Rao, C. S.; Vernachio, J.; Hutchins, J.; Hall, A.; Kolykhalov, A.; Henson, G.; Chamberlain, S. Bioorg. Med. Chem. Lett. 2011, 21, 6007-6012
21. Chamberlain, S.; Hutchins, J.; Madela, K.; McGuigan, C.; Vernachio, J.; Aljarah, M.; Gilles, A. Patent Appl. WO2010081082, 2010.
22. A recent addition to the patent literature demonstrated that using 2 equiv of the uronium reagent HATU with a functionalized phosphoric acid could be used to form this prodrug in 90% yield on 1 g scale. The addition of quinine resulted in a 6.7:1 phosphorus diastereomer mixture. Tran, K.; Eastgate, M. D.; Janey, J.; Chen, K.; Rosso, V. W. Patent Appl. WO2014008236, 2014.
23. Ross, B. S.; Reddy, P. G.; Zhang, H.-R.; Rachakonda, S.; Sofia, M. J. J. Org. Chem. 2011, 76, 8311-8319
24. Ross, B. S.; Sofia, M. J.; Reddy, P. G.; Rachakonda, S.; Zhang, H.-R. WO2011123668, 2011.
25. Butler, T.; Cho, A.; Kim, C. U.; Saunders, O. L.; Zhang, L. WO2009132135, 2009.
26. Bjorsvik, H.-R.; Priebe, H.; Cervenka, J.; Aabye, A. W.; Gulbrandsen, T.; Bryde, A. C. Org. Process Res. Dev. 2001, 5, 472-478
27. Dahlhoff, W. V.; Koster, R. J. Org. Chem. 1977, 42, 3151-3157
28. Yurkevich, A. M.; Kolodkina, I. I.; Varshavskaya, L. S.; Borodulina-Shvets, V. I.; Rudakova, I. P.; Preobrazhenskii, N. A. Tetrahedron 1969, 25, 477-484
29. Sekine, M.; Aoyagi, M.; Ushioda, M.; Ohkubo, A.; Seio, K. J. Org. Chem. 2005, 70, 8400-8408
30. Jegourel, D.; Delepee, R.; Breton, F.; Rolland, A.; Vidal, R.; Agrofoglio, L. A. Bioorg. Med. Chem. 2008, 16, 8932-8939
31. It remains to be determined whether arylboronic acids in general represent a genotoxic hazard. O'Donovan, M. R.; Mee, C. D.; Fenner, S.; Teasdale, A.; Phillips, D. H. Mutat. Res. 2011, 724, 1-6. Beyond preclinical development, the potential for PBA to be a genotoxic impurity in 3 would need to be considered. Methods to control residual arylboronic acids in APIs are discussed in http://www.andersonsprocesssolutions.com/controlling-residual- arylboronic-acids-as-potential-genotoxic-impurities-in-apis/#-ednref1 (Accessed 01 April 2014).
32. Constable, D. J. C.; Curzons, A. D.; Cunningham, V. L. Green Chem. 2002, 4, 521-527
33. Cumulative process mass intensity defined as [total mass of substrates, reagents, and reaction solvents (g)]/[mass of isolated product (g)]. Does not include contributions due to workup, isolation, and purification of products. See PMI calculator: http://www.acs.org/content/acs/en/greenchemistry/industry- business/pharmaceutical.html (Accessed 07 April 2014).
34. Li, C.-J.; Trost, B. M. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 13197-13202
35. According to the procedure described in the following patent: Storer, R.; Moussa, A.; Chaudhuri, N.; Waligora, F. Patent Appl. WO2004052899, 2004.